| Patient | Ann Richards |
|---|---|
| Date of birth | 1962-09-01 |
| Identifiers | MRN HR-ML019-SYN; SSN (made up) 000-19-3381 |
| Document date | 2026-08-11 |
| Author | Rosalind Teague, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Six-month bone health review, three months after the first zoledronic acid infusion. [S]
Ms. Richards returns three months after her first zoledronic acid infusion. The evening after the infusion she had aching muscles and a temperature of 37.9 °C, which settled with acetaminophen and were gone on the third day; she has had no symptoms since. She has had no muscle cramps, tingling, jaw pain, or thigh or groin pain. She takes vitamin D3 2000 units a day and keeps her calcium at about 1200 mg a day from food. She does the home balance program three times a week, walks most days, and has had no falls. She came fasting this morning for her blood tests. She has had no alcohol. [S]
| Element | Detail |
|---|---|
| Infusion reaction | Aches and 37.9 °C for two days after the dose, settled with acetaminophen |
| Drug safety | No cramps, tingling, jaw pain, or thigh or groin pain |
| Supplements and diet | D3 2000 units daily; calcium about 1200 mg a day from food |
| Falls | None; home balance program three times a week |
| Recovery | No alcohol; no cravings |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No fever or fatigue since the third day after the infusion |
| Musculoskeletal | Negative | No bone, thigh, or groin pain; no muscle cramps |
| Ears, nose, mouth, and throat | Negative | No jaw pain, loose teeth, or mouth sores |
| Eyes | Negative | No eye pain or redness |
| Psychiatric | Negative | Mood good; no cravings; no thoughts of self-harm |
5 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Cholecalciferol (vitamin D3) 50 mcg (2000 units) oral tablet, one tablet daily | One tablet by mouth daily | Oral route | 2026-02-10 | active | S |
| Zoledronic acid 5 mg in 100 mL intravenous infusion over 30 minutes, once every 12 months | Once every 12 months, given in the clinic infusion room after a calcium and creatinine check | Intravenous route | 2026-05-12 | active | S |
| Acetaminophen 500 mg oral tablet, two tablets every 6 hours as needed for aches or fever for up to three days after the infusion (no more than 3 g a day) | Two tablets every 6 hours as needed for up to three days after the infusion | Oral route | 2026-05-12 to 2026-05-15 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-08-11 | Body height | 164 | cm | S |
| 2026-08-11 | Body weight | 66 | kg | S |
| 2026-08-11 | Body mass index (BMI) [Ratio] | 24.5 | kg/m2 | S |
| 2026-08-11 | Systolic blood pressure | 122 | mm[Hg] | S |
| 2026-08-11 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 2026-08-11 | Heart rate | 68 | /min | S |
| 2026-08-11 | Respiratory rate | 14 | /min | S |
| 2026-08-11 | Body temperature | 36.7 | Cel | S |
| 2026-08-11 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-08-11 | Collagen crosslinked C-telopeptide [Mass/volume] in Serum or Plasma | 190 | pg/mL | Postmenopausal reference interval 104 to 1008 pg/mL; a fall of more than about 30 percent on antiresorptive therapy indicates response | Normal | S |
| 2026-08-11 | Calcium [Mass/volume] in Serum or Plasma | 9.3 | mg/dL | 8.6-10.3 mg/dL | Normal | S |
Vital signs recorded on 2026-08-11; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; weight 66.0 kg |
| Mouth | No exposed bone or gum swelling |
| Musculoskeletal | No thigh tenderness; full painless hip movement |
| Gait and balance | Timed Up and Go 9 seconds; tandem stance 20 seconds |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Low bone mass (osteopenia) of the lumbar spine and hip on DXA, lowest T-score -2.3 at the lumbar spine (femoral neck -2.0, total hip -1.7), with a 10-year FRAX risk above the treatment thresholds (major osteoporotic fracture 22 percent, hip 3.6 percent); not osteoporosis by T-score, but meets the AACE 2020 clinical criteria for osteoporosis (low bone mass with a FRAX risk above threshold) | active | confirmed | M85.89 | S — Synthetic modern DXA and FRAX classification linked to her publicly described osteopenia (early osteoporosis) after a fall with a hand fracture. |
| Alcohol use disorder in sustained remission for more than fifteen years, since treatment; no alcohol since | active | confirmed | F10.21 | S — Synthetic modern coding of her publicly described heavy drinking and long recovery; listed because remission protects bone and lowers fall risk, and it is reviewed at each visit. |
| History of falls: a fall from standing height with a hand fracture last year (and, in one account, a second fall with an ankle fracture); no falls since | active | confirmed | Z91.81 | S — Synthetic modern entry linked to her publicly described falls and fractures. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Bone-turnover marker (fasting serum CTX) | Baseline, then 3 to 6 months after starting or changing therapy | Completed today | 190 pg/mL, 66 percent below the baseline of 560; response and adherence confirmed |
| Laboratory | Serum calcium | Before each zoledronic acid dose, and after the first dose if symptoms suggest hypocalcemia | Completed today | 9.3 mg/dL, normal; checked with the CTX sample |
| Laboratory | 25-hydroxyvitamin D | After repletion until 30 ng/mL or more; then yearly | Up to date | 38 ng/mL in May; next with the pre-infusion tests in May |
| Medication safety | Acute-phase reaction after zoledronic acid | After the first dose | Completed today | Aches and 37.9 °C for two days, settled with acetaminophen; acetaminophen offered again for the next dose |
| Medication safety | Osteonecrosis of the jaw and atypical femoral fracture symptoms | At each visit on antiresorptive therapy | Completed today | No jaw pain or exposed bone; no thigh or groin pain; routine dental care twice a year |
| Imaging | Central DXA of the spine and hip | Every 1 to 2 years on therapy until stable, on the same scanner | Up to date | Due two years after starting therapy, on the same scanner |
| Examination | Standing height by stadiometer | Yearly; vertebral imaging again if height falls 2 cm or more | Up to date | 164.0 cm, unchanged |
| Examination | Fall-risk screen | Yearly, and with any fall | Completed today | Timed Up and Go 9 seconds, tandem stance 20 seconds; no falls |
| Survey | FRAX 10-year fracture risk | At baseline, when risk factors change, and at the drug-holiday decision | Up to date | No change in risk factors; next at the drug-holiday decision |
| Survey | Calcium intake assessment | At baseline and yearly | Up to date | About 1200 mg a day from food |
| Medication safety | Drug-holiday eligibility | After 3 yearly zoledronic acid doses or 5 years of an oral bisphosphonate | Not indicated | One dose so far; reassess after the third yearly dose |
| Self-management | Balance and strength exercise program | With a history of falls or impaired balance | Up to date | Home program three times a week |
| Self-management | Recovery check (alcohol, cravings, stress) | Every visit | Completed today | No alcohol; no cravings |
| Survey | Suicide-risk review and safety plan, with the 988 Suicide & Crisis Lifeline | Every visit | Completed today | No thoughts of suicide or self-harm; the 988 Suicide & Crisis Lifeline is saved in her phone |
Goal progress:
Guideline basis: CMID: Clinical Monitoring Intelligence Database, osteoporosis monograph (2026); The clinician's guide to prevention and treatment of osteoporosis (2022); American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis, 2020 Update (2020); Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Clinical Practice Guideline (2019); STEADI: Stopping Elderly Accidents, Deaths, and Injuries (2026); VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders (2021); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024)
Follow-up: Adult preventive visit in October. Second zoledronic acid dose in May with pre-infusion tests. Call for jaw pain, thigh or groin pain, or any fall. Next scheduled visit 2026-10-06: adult preventive visit. [S]